Polymers for gene delivery across length scales

Purpose: Synthetic polymer-based gene delivery vectors have been studied for two decades but remain far less efficient than viral vectors. The review addresses the need for improved design criteria and new synthetic strategies across nano-, micro-, and macroscale delivery systems to overcome formulation, organism-level, and cellular barriers to DNA delivery.

Hypothesis: As a review, this paper does not test a single formal hypothesis. Its central premise is: if polymeric vectors are rationally designed or combinatorially screened at the appropriate length scale, then they can better overcome the biological barriers to gene delivery, improving transfection efficiency, biocompatibility, targeting, and clinical potential relative to conventional synthetic vectors.

Aims: Review recent developments in polymer-based gene delivery vector design at nanoscale, microscale, and macroscale. - Outline the formulation, organism-level, and cellular barriers that gene delivery vectors must overcome, and the corresponding material design criteria. - Discuss combinatorial synthesis and high-throughput screening approaches for discovering more efficient synthetic vectors. - Describe polymer-based modification of viral vectors to reduce immunogenicity, improve biodistribution, and alter tropism. - Summarize clinical applications and future challenges in polymeric gene delivery.

Delivery system: Nanoscale vectors (<1 μm; predominantly <200 nm): Cationic polymers and lipids that self-assemble with polyanionic nucleic acids into polyelectrolyte complexes. Polymers include polylysine, branched/linear/degradable PEI, PEGylated PEIs, cyclodextrin-based polymers, poly(α-(4-aminobutyl)-L-glycolic acid), imidazole-containing polymers, poly(propylacrylic acid), polyacetals, polyphosphoesters, polyphosphazenes, pDMAEMA, HPMA, poly(amidoamine)s, PAMAM dendrimers, Pluronics/PINCs, poly(β-amino ester)s, chitosan, peptides, and inorganics/ceramics. Payloads: plasmid DNA, other DNA forms, and RNA. - Microscale vectors (1–10 μm): Polymer microspheres for DNA vaccines and localized DNA delivery, primarily targeting antigen-presenting cells. Materials include PLGA, polyorthoester, cationic microparticles, PBAE-containing microspheres, polyanhydride microspheres, and hyaluronan microspheres. DNA is encapsulated or adsorbed. - Macroscale vectors (2D surfaces or 3D scaffolds): Scaffolds and surfaces for tissue engineering and localized gene delivery. Materials include hyaluronic acid/collagen hydrogels, crosslinked PEG hydrogels, genetically engineered protein hydrogels, 2D cationic surfaces, 3D hydrophobic scaffolds, inorganic surfaces, polyelectrolyte thin films, and thermoresponsive hydrogels. DNA can be delivered alone or pre-complexed with polycations such as PEI or polylysine. - Viral vector modification: PEGylation, pHPMA coating, and heterobifunctional PEG for attaching targeting ligands such as FGF2 or VEGF.

Approach: Narrative literature review. No primary experiments are reported. The review synthesizes preclinical and clinical studies across three length scales. - In vitro context: Cell culture transfection studies, biophysical characterization of polymer/DNA complexes, and high-throughput screening of combinatorial libraries. - In vivo context: Animal models of cancer, DNA vaccination, and tissue engineering; biodistribution and liver/tumor infectivity studies. - Clinical context: Approximately 65% of gene therapy clinical trials use viral vectors. Two microscale polymeric systems are noted in clinical trials: a PLGA-based microsphere DNA vaccine against human papillomavirus (Phase II) and cancer (Phase I/IIa) by MGI Biologics, and a cationic PLGA microsphere HIV DNA vaccine (Phase I) by Chiron Corporation with the NIH.

Key methods: The review summarizes methods from cited primary studies rather than presenting new methods: - Biophysical characterization of polymer/DNA complexes: electrostatic complexation, DNA condensation, nuclease protection. - Transfection assays and cytotoxicity measurements. - Combinatorial library synthesis and high-throughput screening of peptoids, cationic lipids, and poly(β-amino ester)s. - In vivo biodistribution, blood circulation time, liver/tumor infectivity, and tumor growth inhibition. - DNA release kinetics from microspheres and thin films, including pH-triggered release. - Clinical trial outcomes for DNA vaccines.

Key results: Representative findings highlighted in the review: - Combinatorial peptoid library: 67 structures synthesized from 13 side chains; 24 tested for transfection. Optimal activity required a repeating motif of two phenyl groups followed by a primary amine-terminated side chain. Minor changes, such as p-hydroxyl substitution, eliminated transfection even though DNA condensation and nuclease protection were preserved. - Cationic lipid library: 16 unique structures. Transfection efficiency increased with hydrophobicity; a di-C14-tailed lipid gave maximum transfection and lowest cytotoxicity. - Poly(β-amino ester) libraries: Initial library of 140 structures from 7 diacrylates and 20 amines yielded two reagents comparable to branched PEI and Lipofectamine 2000. A semi-automated library of 2,350 PBAE structures from 94 amines and 25 diacrylates identified 46 new structures with transfection efficiencies exceeding optimized PEI. Best reagents commonly contained a hydrophobic residue. - Viral vector modification: FGF2-targeted PEG-adenovirus showed tumor infectivity of 19,000 RLU/mg tissue versus 6,500 RLU/mg for native adenovirus, and liver infectivity of 4,000 RLU/mg versus 80,000 RLU/mg for native adenovirus. pHPMA-coated adenovirus reduced liver infection by several orders of magnitude and increased blood circulation time. - Microscale DNA release: Poly(orthoester) microspheres released DNA in a pH-sensitive manner; delaying DNA vaccine release influenced tumor growth in animal models. PLGA/PBAE composite microparticles slowed tumor growth more than PLGA alone. - Macroscale thin films: Layer-by-layer DNA/polymer films approximately 20 nm thick achieved near zero-order DNA release over 30 hours, and the released DNA was transcriptionally active.

Interpretation: The author concludes that polymeric gene delivery remains in its infancy and that its entry into mainstream clinical use depends on improving delivery efficiency. Combinatorial synthesis can accelerate vector discovery, but structure–function relationships and mechanisms remain poorly understood. Viral vectors can be made more “synthetic” through polymer modification to reduce immunogenicity and alter tropism. Future progress will require integrated efforts across materials science, chemistry, engineering, biology, and medicine, as well as computational and robotic approaches to library design and screening.

Limitations: This is a narrative review, not a systematic review or meta-analysis; no quantitative synthesis or risk-of-bias assessment is provided. - Synthetic vectors remain orders of magnitude less efficient than viral vectors. - There is a significant gap in mechanistic understanding of how synthetic vectors deliver DNA to the nucleus. - Combinatorial libraries cover only a small fraction of the potential parameter space. - PLGA-based DNA delivery faces issues including acidic degradation environments, incomplete DNA release, slow release, and shear-induced DNA damage during encapsulation. - DNA vaccines generally have low potency, particularly in humans. - Viral vector modification can be limited by crosslinking, residual immunogenicity, and manufacturing challenges. - The review is from 2006, so it predates modern nucleic acid delivery advances such as CRISPR, mRNA lipid nanoparticles, and newer biodegradable polymer systems. - Clinical data on polymeric gene delivery remain limited at the time of publication.